CVS takes on Mylan’s EpiPen with much cheaper version of an alternative | Traderszone

- Home
- TZ Newswire
- Business Features
- ETF's
- Futures
- Options
- Real Estate
- Stocks
- TZ Featured Lists
- TZ Latest News
- TZ Resources
Editorial Archives
Editorial Archives

Published in TZ Latest News 12 January, 2017 by The TZ Newswire Staff

CVS takes on Mylan’s EpiPen with much cheaper version of an alternative

Drugstore chain is selling a treatment for life-threatening allergies at roughly a sixth of the price of the EpiPen.
read more

See also
- Next Article Herbalife Distributors to Receive Refund From FTC
- Previous Article Earnings Outlook: Netflix earnings: What to expect from the streaming giant
Editorial Calender

January 2017

M T W T F S S

1

2 3 4 5 6 7 8

9 10 11 12 13 14 15

16 17 18 19 20 21 22

23 24 25 26 27 28 29

30 31

« Dec Feb »
Recent Tags

Abnormal Returns Active management Asia Brave New World Business Chart.ly Chicago Board Options Exchange CNBC Commodities and Futures Covestor Day Trading Derivatives Equities Exchange Exchange-traded fund Funds Gawker.com GDP Gold Gold as an investment Gross domestic product High-frequency trading Hong Kong Investing Japan Market maker May 6 2010 flash crash Mutual fund National Association of Home Builders New York Mercantile Exchange Option S&P 500 SEC Standard & Poor Stock Stocks and Bonds Stock trader StockTwits Timothy Sykes Tokyo Trade Twitter U.S. Dollar Index U.S. Securities and Exchange Commission United States dollar